Recent Advances in Antiphospholipid Syndrome
A special issue of Immuno (ISSN 2673-5601).
Deadline for manuscript submissions: 30 June 2025 | Viewed by 8960
Special Issue Editor
Interests: internal medicine; management of internal medicine; thrombotic disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear colleagues,
Although guidelines of international society of thrombosis and haemostatis (ISTH) and America rheumatology association are available from several years to suggest diagnosis and treatments for primary and secondary antiphospholipid syndrome several issues are frequently debated in the daily clinical practice.
Immunomediated thrombosis recognises different pathophysiological mechanisms from traditional arterial and venous thrombosis and new pathophysiological mechanisms are recently described.
Furthermore, clinical presentation differs in young patients or adult patients, and also, therapeutic support offers different outcomes in patients with primary or secondary antiphospholipid syndrome.
Furthermore, the follow-up strategy of carriers of asymptomatic abnormal values of antiphospholipid antibodies is still debated.
Therefore, this Special Issue is dedicated to scholars that may offer their clinical and laboratory experience in the management of clinical overt antiphospholipid syndrome or asymptomatic carriers of antiphospholipid antibodies.
We think that this is still an intriguing clinical issue, and we hope that scholars around world agree.
Dr. Pierpaolo Di Micco
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Immuno is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antiphospholipid syndrome
- antiphospholipid antibodies
- lupus anticoagulant
- venous thromboembolism
- miscarriage
- atherothrombosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
